SOLICITATION NOTICE
B -- Evaluating Molecular Markers in Endometrial Hyperplasia
- Notice Date
- 8/6/2014
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 1050, Frederick, Maryland, 21702, United States
- ZIP Code
- 21702
- Solicitation Number
- N02CP42619-57
- Archive Date
- 9/4/2014
- Point of Contact
- Reyes Rodriguez, Phone: 240-276-5442
- E-Mail Address
-
reyes.rodriguez@nih.gov
(reyes.rodriguez@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), plans to procure on a sole source basis services to establish the prevalence of molecular markers in a large set of endometrial hyperplasia samples covering the whole range of low grade to high grade dysplasia in women participating in the Kaiser Permanente Portland Health Maintenance Organization (HMO) from Kaiser Foundation Hospitals, Kaiser Permanente Northwest, 1800 Harrison Street, 16th Floor, Oakland, CA 94612. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System code is 541990 and the business size standard is $14.0 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance is twelve (12) months from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. Endometrial cancer is the most common gynecological cancer in the U.S., with an estimated 43,500 incident cases and 8,000 related deaths in 2010. Obesity is a strong risk factor for endometrial cancer, and data in some populations suggest that rates of endometrial cancer and its precursors are rising, mirroring the growing prevalence of obesity. Most endometrial cancers develop slowly through progression of well characterized precursors, many of which regress with progesterone treatment or are curable with hysterectomy. Thus, early detection of endometrial cancer precursors can enable prevention of many endometrial cancers and reduce mortality. Using DNA methylation profiling in NCI studies, researchers from the Division of Cancer Epidemiology and Genetics have identified a panel of markers that are strongly and specifically linked to endometrial cancer and may have value for early detection. There is some evidence suggesting that these markers can be detected in endometrial hyperplasia samples, but it is not clear which markers are present in which grade of hyperplasia. Most endometrial hyperplasias do not progress to cancer. The contractor shall: • Identify 500 eligible women with endometrial hyperplasia diagnosed between 1995 and 2010 at Kaiser Permanente Northwest, Portland OR, matched by time of diagnosis to previously selected endometrial hyperplasias that progressed to cancer. • Send anonymized pathology reports for review by NCI staff. • Retrieve 300 tissue blocks of endometrial hyperplasia samples selected by NCI staff after review of pathology reports. • Conduct a histological review of up to 150 cases of endometrial hyperplasia samples to confirm findings from the pathology reports. • Send 300 archived blocks from eligible endometrial hyperplasia samples to NCI Kaiser Permanente Northwest, along with NIH, has previously conducted a study of endometrial cancers and preceding endometrial hyperplasia. The current proposal extends the analysis of molecular markers in a large series of endometrial hyperplasias covering the whole diagnostic spectrum. The current samples need to be matched to the previously collected endometrial hyperplasias that progressed to endometrial cancer from the same population. Since from the population at Kaiser Permanente Northwest has been previously sampled, efforts need to be extend in the same population to ensure consistency of our findings over time. This notice is not a request for competitive quotation. However, if any interested party, especially small business believes it can meet the above requirement, it may submit a proposal or quote for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 4 PM EST, on August 20, 2014. All responses and questions must be in writing and faxed 240-276-5399 or emailed to Reyes Rodriguez, Contracting Specialist via electronic mail at reyes.rodriguez@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through sam.gov. Reference: N02CP42619-57 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF/N02CP42619-57/listing.html)
- Place of Performance
- Address: Contractor's site, United States
- Record
- SN03452692-W 20140808/140807022349-603fedebdd15dd0fa30df23afd9a6842 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |